Medicine 2026-03-11 3 min read

The cosmetic surgery boom is outpacing the regulations meant to keep it safe

Experts writing in The BMJ call for consistent UK-wide rules, mandatory training standards, and advertising controls as the global cosmetic market heads toward $180 billion.

BMJ Group

How did we arrive at a point where someone with no medical training can legally inject dermal fillers into a patient's face in most of the United Kingdom? The answer involves a regulatory framework that was designed for a different era, a booming global market that does not wait for rules to catch up, and a blurring line between surgical and non-surgical procedures that existing categories cannot contain.

In a new analysis published in The BMJ in March 2026, Danielle Griffiths of the University of Liverpool and colleagues lay out the case for comprehensive reform of cosmetic procedure regulation in the UK.

A $180 billion market with inconsistent oversight

The global market for cosmetic procedures is projected to exceed $180 billion by 2033. Invasive surgical procedures like tummy tucks and breast augmentation are regulated, requiring qualified medical professionals and clinical settings. But non-surgical procedures, including botox injections and dermal fillers, face far less oversight despite becoming increasingly invasive.

That distinction is the core problem. Non-surgical procedures were once clearly separable from surgery: a facial peel is not a facelift. But the category now includes injectable treatments that carry genuine medical risks, from inflammation and nerve damage to vision problems and anxiety. Side effects of botox range from minor irritation to serious neurological complications. Complications from breast surgery and tummy tucks include wound separation, infection, and seromas, fluid-filled lumps under the skin.

Deaths remain rare. But evidence suggests harms are increasing, particularly from cosmetic procedures performed abroad, where patients may face unfamiliar clinical standards and limited recourse when things go wrong.

No UK-wide tracking of complications

There is no unified reporting or tracking system for complications from private cosmetic procedures across the United Kingdom. Many complications go unreported entirely. When patients experience problems from procedures performed by non-NHS providers, the resulting costs often fall on the NHS, but even those costs are probably underestimated because tracking is incomplete.

The authors note that recent UK government proposals to regulate non-surgical cosmetic procedures are moving slowly, and substantial gaps remain. The four UK nations do not share a consistent regulatory framework, meaning a procedure that requires a licensed practitioner in one country may not in another.

What Australia and other countries have done

The analysis points to reforms adopted by Australia and other countries as models. These include requiring that high-risk invasive procedures, both surgical and non-surgical, be performed only by trained healthcare professionals with standardized qualifications. A single set of guidelines covering training, assessment, consultation, and consent provides a consistent framework rather than a patchwork of local rules.

Advertising controls are another critical component. Social media has made cosmetic procedures aspirational and normalized among younger demographics, often without adequate information about risks. Accredited registers of qualified practitioners give consumers a reliable way to verify credentials.

The cosmetic tourism dimension

Cosmetic tourism complicates the regulatory picture further. Patients travel to countries with lower costs and less regulation, then return home to manage complications. The NHS bears these costs without having any control over the conditions under which the procedures were performed.

The authors argue that reducing cosmetic tourism requires both domestic regulatory reform, making the UK market safer and more trustworthy, and public education about the genuine risks of undergoing procedures abroad.

An opinion piece, not a study

This is an expert analysis and policy argument published in The BMJ, not an empirical study with original data. The authors synthesize existing evidence and regulatory comparisons to make their case, but they do not present new research on complication rates or patient outcomes.

The scale of harm is difficult to quantify precisely because of the reporting gaps the authors themselves identify. Whether tighter regulation would reduce complications, or simply shift procedures to unregulated settings, is an open question that the analysis raises but cannot answer.

The political and practical challenges of implementing UK-wide regulation across four nations with separate health systems are substantial and may explain why reform is proceeding slowly.

Still, the fundamental point is hard to dispute: a multibillion-dollar industry performing increasingly invasive procedures on the human body operates under a regulatory framework that does not match the current risks.

Source: Griffiths D et al. Published in The BMJ, March 2026. University of Liverpool. The article calls for consistent regulation, standardized training requirements, advertising controls, and accredited practitioner registers across all four UK nations.